<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>汉靓的医药科技前沿 | wechat-feeds</title><link>http://MzUzMDE3NzI4OQ.favicon.privacyhide.com/favicon.ico</link><description>专注于生物医药领域，分享最前沿的技术，最领先的商业模式，最新的政策，以及对生物医药行业发展的所思所想</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 25 Jan 2021 23:49:59 +0800</pubDate><image><url>http://MzUzMDE3NzI4OQ.favicon.privacyhide.com/favicon.ico</url><title>汉靓的医药科技前沿 | wechat-feeds</title><link>http://MzUzMDE3NzI4OQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【87】从今年的ASH会议，谈BioMarin、UniQure等公司的血友病基因疗法最新进展</title><link>https://mp.weixin.qq.com/s/k6cqe32vktZqbsqa8FWiDA</link><description></description><content:encoded><![CDATA[【87】从今年的ASH会议，谈BioMarin、UniQure等公司的血友病基因疗法最新进展]]></content:encoded><pubDate>Sun, 20 Dec 2020 00:01:21 +0800</pubDate></item><item><title>【86】燃石和泛生子的2020Q3业绩跟踪：肿瘤早筛项目均有所突破</title><link>https://mp.weixin.qq.com/s/z0UjXfxZw2oDFpPIkspf9Q</link><description></description><content:encoded><![CDATA[【86】燃石和泛生子的2020Q3业绩跟踪：肿瘤早筛项目均有所突破]]></content:encoded><pubDate>Sun, 06 Dec 2020 20:05:19 +0800</pubDate></item><item><title>【85】Illumina和Guardant的2020Q3业绩跟踪：疫情下的NGS产业动态</title><link>https://mp.weixin.qq.com/s/Aiw4s3_tG1Es_-tjIc5LJg</link><description></description><content:encoded><![CDATA[【85】Illumina和Guardant的2020Q3业绩跟踪：疫情下的NGS产业动态]]></content:encoded><pubDate>Tue, 17 Nov 2020 22:04:41 +0800</pubDate></item><item><title>【84】从Thrive、Freenome、Exact等几家早肿瘤早筛公司，谈Illumina收购Grail的战略布局</title><link>https://mp.weixin.qq.com/s/YA3OYgqvhc210uBDIgvWNw</link><description></description><content:encoded><![CDATA[【84】从Thrive、Freenome、Exact等几家早肿瘤早筛公司，谈Illumina收购Grail的战略布局]]></content:encoded><pubDate>Sun, 01 Nov 2020 00:33:02 +0800</pubDate></item><item><title>【83】荣昌生物招股书解读之二：从RC48谈Her2靶向抗体偶联药物（ADC）</title><link>https://mp.weixin.qq.com/s/BY_NQResEqliSwltlPFWtw</link><description></description><content:encoded><![CDATA[【83】荣昌生物招股书解读之二：从RC48谈Her2靶向抗体偶联药物（ADC）]]></content:encoded><pubDate>Sun, 20 Sep 2020 15:18:19 +0800</pubDate></item><item><title>【82】荣昌生物招股书解读之一：从泰它西普（Telitacicept）谈系统性红斑狼疮新药进展</title><link>https://mp.weixin.qq.com/s/af5b_6hjlTwDlylM84tX-A</link><description></description><content:encoded><![CDATA[【82】荣昌生物招股书解读之一：从泰它西普（Telitacicept）谈系统性红斑狼疮新药进展]]></content:encoded><pubDate>Sun, 30 Aug 2020 13:50:30 +0800</pubDate></item><item><title>【81】从Illumina、Guardant、燃石和泛生子的二季报谈NGS行业的最新动态</title><link>https://mp.weixin.qq.com/s/Xm9_kddnmoLk_1OyYuUoMw</link><description></description><content:encoded><![CDATA[【81】从Illumina、Guardant、燃石和泛生子的二季报谈NGS行业的最新动态]]></content:encoded><pubDate>Sun, 16 Aug 2020 20:26:18 +0800</pubDate></item><item><title>【80】再谈BCL-2：从亚盛的BCL-2抑制剂和阿斯利康BTK的合作谈起</title><link>https://mp.weixin.qq.com/s/Rtn_Ljw8ioHa2gM0vSr-Tw</link><description></description><content:encoded><![CDATA[【80】再谈BCL-2：从亚盛的BCL-2抑制剂和阿斯利康BTK的合作谈起]]></content:encoded><pubDate>Sat, 01 Aug 2020 18:20:58 +0800</pubDate></item><item><title>【79】再谈CDK4/6: 从嘉和生物的招股书说起</title><link>https://mp.weixin.qq.com/s/F3pSMaEIVeO6q2DNl_uRJg</link><description></description><content:encoded><![CDATA[【79】再谈CDK4/6: 从嘉和生物的招股书说起]]></content:encoded><pubDate>Sun, 19 Jul 2020 09:53:11 +0800</pubDate></item><item><title>【78】CD47系列报告之二：Trillium、ALX和宜明昂科的Fc融合蛋白</title><link>https://mp.weixin.qq.com/s/H_wnZTy07Dt3ofBpKju-zg</link><description></description><content:encoded><![CDATA[【78】CD47系列报告之二：Trillium、ALX和宜明昂科的Fc融合蛋白]]></content:encoded><pubDate>Sun, 05 Jul 2020 12:37:38 +0800</pubDate></item></channel></rss>